| Income Statement | 2025-09-30 | 2024-09-30 | ||
|---|---|---|---|---|
| Research and development | 6,418,334 | 4,925,001 | ||
| General and administrative | 8,783,997 | 8,148,929 | ||
| Stock-based compensation general and administrative | 8,320,419 | 7,498,817 | ||
| Total operating expenses | 23,522,750 | 20,572,747 | ||
| Operating loss | -23,522,750 | - | ||
| Interest income | 36,373 | - | ||
| Interest expense | 218,032 | - | ||
| Total other income (expense), net | -181,659 | - | ||
| Loss before income taxes | -23,704,409 | -20,572,747 | ||
| Income tax expense | 1,056,960 | 576,000 | ||
| Net loss | -24,761,369 | -21,148,747 | ||
| Net loss per share diluted (in dollars per share) | -0.34 | -0.31 | ||
| Net loss per share - basic (in dollars per share) | -0.34 | -0.31 | ||
| Weighted average common shares outstanding basic (in shares) | 73,267,969 | 68,053,607 | ||
| Weighted average common shares outstanding diluted (in shares) (in shares) | 73,267,969 | 68,053,607 | ||
CITIUS ONCOLOGY, INC. (CTOR)
CITIUS ONCOLOGY, INC. (CTOR)